[BNews]

Featured Articles

Apple Stock Forecast Could Rocket on ‘ Says Analyst Dan Ive

Bitcoin’s $1 Billion Liquidation Tsunami: Just Another Dip Or Is The Bull Run Over?

Does Quantum Computing Pose a Threat to Bitcoin?

How Solar and Farming Can Thrive Together

Tech Companies Warn H-1B Visa Holders to Avoid Foreign Travel

According to Adam Livingston, you have 5 years to stack Bitcoin before AI takes your soul

Coinbase’s Base Blockchain Now ‘Exploring’ Token As US Crypto Regulatory Environment Turns

Meta’s Smart Glasses Might Make You Smarter. They’ll Certainly Make You More Awkward

Investors Should Ask: Who Wins More From This $6.3 Billion CoreWeave-Nvidia Agreement?

JPMorgan Raises Apple Stock Forecast Because iPhone 17 “Surprised Positively”

Apple Stock Forecast Could Rocket on ‘ Says Analyst Dan Ive

Bitcoin’s $1 Billion Liquidation Tsunami: Just Another Dip Or Is The Bull Run Over?

Does Quantum Computing Pose a Threat to Bitcoin?

How Solar and Farming Can Thrive Together

Tech Companies Warn H-1B Visa Holders to Avoid Foreign Travel

According to Adam Livingston, you have 5 years to stack Bitcoin before AI takes your soul

Coinbase’s Base Blockchain Now ‘Exploring’ Token As US Crypto Regulatory Environment Turns

Meta’s Smart Glasses Might Make You Smarter. They’ll Certainly Make You More Awkward

Investors Should Ask: Who Wins More From This $6.3 Billion CoreWeave-Nvidia Agreement?

JPMorgan Raises Apple Stock Forecast Because iPhone 17 “Surprised Positively”

Featured STOCK

  • Bitmine Expands Ethereum Treasury As Valuation And Momentum Send Mixed Signals

    Bitmine Immersion Technologies acquired 50,928 ETH, taking its total Ethereum holdings to more than 4.4 million. The move reinforces Bitmine's role as a large Ethereum treasury and expands its exposure to ETH staking. The company, which trades as NYSEAM:BMNR, last closed at $19.57. Bitmine Immersion Technologies (NYSEAM:BMNR) is leaning further into its Ethereum-focused model with...

  • Tesla vs. Amazon: Which AI Stock Is the Better Buy Now?

    Both companies have seen their shares pull back this year, but one offers a significantly more attractive entry point for investors today. 

  • Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences’ (TYRA) Investment Narrative?

    Tyra Biosciences reported a higher net loss for the fourth quarter and full year 2025, while simultaneously advancing its dabogratinib 3x3 clinical strategy and bolstering its leadership team. This combination of deeper losses and intensified late-stage development around dabogratinib in FGFR3-driven diseases is sharpening investor focus on the company’s precision oncology and rare disease ambitions....